Criticism mounts over India's 'abrupt' approval of COVAXIN
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Sunday
January 29, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
SUNDAY, JANUARY 29, 2023
Criticism mounts over India's 'abrupt' approval of COVAXIN

Coronavirus chronicle

Reuters
06 January, 2021, 04:15 pm
Last modified: 06 January, 2021, 04:28 pm

Related News

  • India's Adani says $2.5 bln share sale on track even as bankers mull changes
  • India's rapid take-up of electric vehicles prompts rethink about long-term fuel needs
  • India's low coal stocks threaten electricity supply: Kemp
  • Two IAF aircraft crash near India's Madhya Pradesh's Morena
  • ‘Intransigence’: India notifies Pakistan of plans to amend Indus Waters Treaty

Criticism mounts over India's 'abrupt' approval of COVAXIN

Health experts questioned why the SEC abruptly recommended approval one day after asking Bharat Biotech for more analysis

Reuters
06 January, 2021, 04:15 pm
Last modified: 06 January, 2021, 04:28 pm
A medic fills a syringe with COVAXIN, an Indian government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials, at the Gujarat Medical Education and Research Society in Ahmedabad, November 26, 2020. REUTERS/Amit Dave/File Photo
A medic fills a syringe with COVAXIN, an Indian government-backed experimental Covid-19 vaccine, before administering it to a health worker during its trials, at the Gujarat Medical Education and Research Society in Ahmedabad, November 26, 2020. REUTERS/Amit Dave/File Photo

Criticism of India's approval of a local Covid-19 vaccine without proof of its efficacy grew on Wednesday after news that a regulatory panel approved the shot just one day after asking the vaccine maker for more evidence it would work.

The recommendations of the Indian drugs regulator's subject expert committee (SEC) released on Tuesday show that the panel asked Bharat Biotech International Ltd to present more efficacy data for its Covid-19 shot before it could consider approving the treatment.

"After detailed deliberation, the committee recommended that the firm ... may perform interim efficacy analysis for further consideration of restricted emergency use approval," the SEC's recommendations in a Jan. 1 meeting show.

The very next day, the committee recommended approving Bharat Biotech's vaccine for "restricted use in emergency situation in public interest as an abundant precaution."

The SEC also separately recommended emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, being produced by India's Serum Institute.

The greenlighting of Bharat Biotech's COVAXIN had already faced criticism from opposition lawmakers and health experts for lack of efficacy data, typically obtained from a large, Phase III human trial - which the manufacturer is still conducting.

News of the SEC's recommendations spurred further criticism.

"Was the Subject Expert Committee (SEC) approval a command performance? This is as serious as it can get," Manish Tewari, an opposition lawmaker, said on Twitter.

Health experts questioned why the SEC abruptly recommended approval one day after asking Bharat Biotech for more analysis.

"The SEC ... appears to have been pressured overnight into reconsidering its decision and giving approval the next day, albeit hedged in by many conditions," the All India People's Science Network, a network of science advocacy groups, said in a statement.

"We are perplexed at the abrupt change in thinking of the SEC from the first two meetings to the third day on which the approval was recommended while apparently discounting the need for efficacy data as the condition of the approval," the All India Drug Action Network, a nonprofit health watchdog, said.

Both Bharat Biotech and government officials have pointed to regulatory provisions that allow for quick drug approval for serious diseases even without Phase III trial data.

Neither India's drugs regulator nor Bharat Biotech responded to Reuters requests for comment on Wednesday.

Regulators also granted approval to Bharat Biotech's vaccine only "in clinical trial mode", unusually cryptic language that left some experts baffled.

"They've introduced terminologies that are confusing," said Giridhar Babu, a professor of epidemiology at the Public Health Foundation of India. "The phrase 'in clinical trial mode' is not generally a term you will see in approvals."

Any confusion around vaccines could harm immunisation programmes by causing distrust, Babu said. "It takes decades of work to build confidence in vaccines."

Top News / World+Biz / South Asia

COVAXIN / India / approval

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Getting gas to India will be even more costly than laying this pipe to China.Photographer: Andrey Rudakov/Bloomberg
    Russia can't replace the energy market Putin broke
  • Ex-MD Mehmood Hossain rejoining National Bank
    Ex-MD Mehmood Hossain rejoining National Bank
  • Photo: UNB
    AL won't run away, rather will continue developing Bangladesh: PM in Rajshahi

MOST VIEWED

  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot
  •  A medical worker checks the IV drip treatment of a patient lying on a bed in the emergency department of a hospital, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China, January 5, 2023. REUTERS/Staff
    China says Covid deaths down by nearly 80 percent
  • Sean Bagley, 14, receives the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    Updated Covid vaccines prevented illness from latest variants -CDC

Related News

  • India's Adani says $2.5 bln share sale on track even as bankers mull changes
  • India's rapid take-up of electric vehicles prompts rethink about long-term fuel needs
  • India's low coal stocks threaten electricity supply: Kemp
  • Two IAF aircraft crash near India's Madhya Pradesh's Morena
  • ‘Intransigence’: India notifies Pakistan of plans to amend Indus Waters Treaty

Features

Nandita Sharmin's journey to give organic skincare a new identity

Nandita Sharmin's journey to give organic skincare a new identity

6h | Mode
Illustration: TBS

'The silver lining is that the worst is sort of behind us': Hamid Rashid, UN economist

10h | Panorama
Photo: Bloomberg

BuzzFeed and AI are a match made in fad city

9h | Panorama
Snipe in flight. Photo: Enam Ul Haque

Baikka Beel: 'A world where snipe work late'

1d | Panorama

More Videos from TBS

Sarika Sabrin is waiting for a good film

Sarika Sabrin is waiting for a good film

21m | TBS Entertainment
Take your football game to the next level at Next Level academy

Take your football game to the next level at Next Level academy

1h | TBS SPORTS
“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

“Investments risky without consistent policy, reliable data”- SK Bashir Uddin

3h | TBS Round Table
What does Shahrukh has in his 770 million dollar property?

What does Shahrukh has in his 770 million dollar property?

23h | TBS Entertainment

Most Read

1
Picture: Collected
Bangladesh

US Embassy condemns recent incidents of visa fraud

2
Illustration: TBS
Banking

16 banks at risk of capital shortfall if top 3 borrowers default

3
Photo: Collected
Splash

Hansal Mehta responds as Twitter user calls him 'shameless' for making Faraaz

4
A frozen Beyond Burger plant-based patty. Photographer: AKIRA for Bloomberg Businessweek
Bloomberg Special

Fake meat was supposed to save the world. It became just another fad

5
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

6
Representational Image
Banking

Cash-strapped Islami, Al-Arafah and National turn to Sonali Bank for costly fund

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]